FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

RAUSCH CARL W 		2. Issuer Name and Ticker or Trading Symbol

Boston Therapeutics, Inc. [ BTHE ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Chief Executive Officer
(Last)          (First)          (Middle)

C/O BOSTON THERAPEUTICS, INC., 354 MERRIMACK STREET, #4 		3. Date of Earliest Transaction (MM/DD/YYYY)

8/14/2017
(Street)

LAWRENCE, MA 01843
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series A Preferred Stock   (2) $0.10   8/14/2017     P      1000000       8/14/2017     (2) Common Stock   1000000   $0.10   1000000   D    
Common Stock Purchase Warrants   (2) $0.15   8/14/2017     P      2000000       8/14/2017   8/14/2022   Common Stock   2000000   $0.15   2000000   D    
Series A Preferred Stock   (2) $0.10   2/2/2018     P      1000000       2/2/2018     (2) Common Stock   1000000   $0.10   1000000   D    
Common Stock Purchase Warrants   (2) $0.15   2/2/2018     P      2000000       2/2/2018   2/2/2023   Common Stock   2000000   $0.15   2000000   D    
Stock Options   (1) $0.20                    8/12/2016   8/12/2021   Common Stock   6000000     6000000   D    
Stock Options   $0.18                    3/25/2015   8/12/2026   Common Stock   500000     500000   D    
Stock Options   $0.10                    9/15/2011   8/12/2026   Common Stock   1500000     1500000   D    

Explanation of Responses:
(1)  The options vest in three equal tranches of 2,000,000 upon the Company the Company raising $1,000,000 in financing, the Company raising $5,000,000 in financing and the Company entering into a significant corporate alliance for substantial marketing and selling of the Company's product portfolio. The initial tranche is exercisable at $0.20 per share, the second tranche will be $0.40 per share and the third tranche will be $0.60 per share, which such vesting is subject to continued employment as an executive with the Company as of the vesting date. The expiration date is five years from the date of grant.
(2)  On August 14, 2017 and February 2, 2018, World Technology East II Limited ("WTE") acquired 10,000 shares of Series A Preferred Stock and common stock purchase warrants to acquire 2,000,000 shares of common stock on each date. Mr. Rausch and Conroy Cheng each equally control WTE and share dispositive and voting control over such securities.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
RAUSCH CARL W
C/O BOSTON THERAPEUTICS, INC.
354 MERRIMACK STREET, #4
LAWRENCE, MA 01843 		X
Chief Executive Officer

Signatures
/s/ Carl W. Rausch 2/12/2018
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.